CBIZ - CBZ Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CBIZ in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CBZ shares.
View CBZ analyst ratings or view top-rated stocks.

CBIZ's stock was trading at $39.12 on January 1st, 2022. Since then, CBZ stock has increased by 13.8% and is now trading at $44.52.
View the best growth stocks for 2022 here.

CBIZ is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our CBZ earnings forecast.

CBIZ, Inc. (NYSE:CBZ) announced its earnings results on Wednesday, October, 27th. The business services provider reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.29 by $0.12. The business services provider had revenue of $282.70 million for the quarter, compared to the consensus estimate of $259.24 million. CBIZ had a net margin of 7.93% and a trailing twelve-month return on equity of 14.56%. The company's revenue for the quarter was up 18.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.36 earnings per share.

CBIZ issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of $2.08-$2.11 for the period, compared to the consensus EPS estimate of $1.92. The company issued revenue guidance of $1.36 billion-$1.38 billion, compared to the consensus revenue estimate of $1.32 billion.

57 employees have rated CBIZ Chief Executive Officer Jerry Grisko on Glassdoor.com. Jerry Grisko has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other CBIZ investors own include Walt Disney (DIS), Veracyte (VCYT), Carnival Co. & (CCL), CRISPR Therapeutics (CRSP), Etsy (ETSY), Gilead Sciences (GILD), Johnson & Johnson (JNJ), KeyCorp (KEY), Altria Group (MO) and NeoGenomics (NEO).

CBIZ trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBZ."

CBIZ's stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (5.19%), Victory Capital Management Inc. (3.72%), Paradice Investment Management LLC (1.83%), Granite Investment Partners LLC (1.45%), Fenimore Asset Management Inc. (1.12%) and Rice Hall James & Associates LLC (0.20%). Insiders that own company stock include Benaree Pratt Wiley, Chris Spurio, Jerome P Grisko, Joseph S Dimartino, Michael P Kouzelos, Rajesh Vashist, Steven L Gerard, Todd J Slotkin and Ware H Grove.
View institutional ownership trends.

Shares of CBZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CBZ stock can currently be purchased for approximately $44.52.

CBIZ (NYSE:CBZ) has a market capitalization of $2.29 billion and generates $1.10 billion in revenue each year. The business services provider earns $70.89 million in net income (profit) each year or $1.92 on an earnings per share basis.

CBIZ employs 6,000 workers across the globe.

CBIZ's mailing address is 6050 OAK TREE BOULEVARD SOUTH SUITE 500, CLEVELAND OH, 44131. The official website for the company is www.cbiz.com. The business services provider can be reached via phone at (216) 447-9000 or via fax at 216-447-9007.